Breaking News, Trials & Filings

Forge’s AAV Gene Therapy Granted Innovation Passport Designation in Krabbe Disease

FBX-101 was created for the treatment of patients with Krabbe disease, a rare neurodegenerative disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Forge Biologics, a member of Ajinomoto Bio-Pharma Services and a manufacturer of genetic medicines, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK’s healthcare regulatory body, granted Innovation Passport designation to the company’s novel AAV gene therapy program, FBX-101, to enter the Innovative Licensing and Access Pathway (ILAP). FBX-101 was created for the treatment of patients with Krabbe disease, a rare neurodegenerative disease that is usually fatal...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters